INTERFERON BETA TREATMENTS, INCLUDING PLEGRIDY (PEGINTERFERON BETA-1A) AND AVONEX (INTERFERON BETA-1A), RECEIVE POSITIVE CHMP OPINION FOR USE DURING PREGNANCY AND BREASTFEEDING
September 23, 2019 at 3:00 AM EDT
- Positive opinion is?supported by data from more than 1,000 real-world pregnancy outcomes
- Data indicate no increased risk of major congenital anomalies after exposure to interferon beta before conception and/or during first trimester
- Data show pregnancy outcomes are in line with general population
MEDIA CONTACT: David Caouette +1 617 679 4945 public.affairs@biogen.com | INVESTOR CONTACT: Joe Mara +1 781 464 2442 IR@biogen.com | |